A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

Código QR

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease

David McMullin,1 David Clark,1 Bill Cavanagh,1 Paul Karpecki,2 Todd C Brady1 1Aldeyra Therapeutics, Inc, Lexington, MA, USA; 2Kentucky Eye Institute, Lexington, KY, USACorrespondence: Todd C BradyAldeyra Therapeutics, Inc, 131 Hartwell Avenue, Suite 320, Lexington, MA, 02421, USATel +1 781 761-4904E...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McMullin D, Clark D, Cavanagh B, Karpecki P, Brady TC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rasp inhibitor dry eye disease inflammation reproxalap lifitegrast eye drop comfort Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/8ed6c8cfce4d4c78970537ad6781fa01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols KK, et al.
Publicado: (2018)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett IV, et al.
Publicado: (2018)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian J, et al.
Publicado: (2020)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose JS, et al.
Publicado: (2019)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez AL
Publicado: (2018)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah RT, et al.
Publicado: (2019)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba CP, et al.
Publicado: (2016)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
por: Epitropoulos AT, et al.
Publicado: (2020)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
por: White DE, et al.
Publicado: (2020)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
por: Jerkins G, et al.
Publicado: (2020)

Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops
por: Ng A, et al.
Publicado: (2018)

Effect of Refresh Plus® preservative-free lubricant eyedrops on tear ferning patterns in dry eye and normal eye subjects
por: Alanazi SA, et al.
Publicado: (2019)

Investigating the potential benefits of a new artificial tear formulation combining two polymers
por: Simmons PA, et al.
Publicado: (2017)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin MR, et al.
Publicado: (2017)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
por: Yeu E, et al.
Publicado: (2020)

Patients’ Experience of Using Eye Drop Guide Device to Aid Self-Administration of Glaucoma Medications
por: Sakiyalak D, et al.
Publicado: (2020)

Development of Lutein-Containing Eye Drops for the Treatment of Dry Eye Syndrome
por: Yi-Zhou Chen, et al.
Publicado: (2021)

Adaptación cultural y validación del cuestionario Ocular Surface Disease Index en una población chilena
por: Traipe,Leonidas, et al.
Publicado: (2020)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
por: Silverstein S, et al.
Publicado: (2020)

Making the diagnosis of Sjögren’s syndrome in patients with dry eye
por: Beckman KA, et al.
Publicado: (2015)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Ocular Surface Changes in Patients with Thyroid Eye Disease: An Observational Clinical Study
por: Allam IY, et al.
Publicado: (2021)

Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains
por: Ebrahimiadib N, et al.
Publicado: (2020)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

Impact of Thermal Pulsation Treatment on Astigmatism Management and Outcomes in Meibomian Gland Dysfunction Patients Undergoing Cataract Surgery
por: Matossian C
Publicado: (2020)

Effectiveness Of Polyethylene Cover Versus Polyethylene Cover With Artificial Tear Drop To Prevent Dry Eye In Critically Ill Patients: A Randomized Controlled Clinical Trial
por: Nikseresht T, et al.
Publicado: (2019)

Ocular manifestations in patients with systemic sclerosis
por: Małgorzata Kozikowska, et al.
Publicado: (2020)

Comparing SPEED and OSDI Questionnaires in a Non-Clinical Sample
por: Hashmani N, et al.
Publicado: (2021)

Effect of topical 3% diquafosol sodium on eyes with dry eye disease and meibomian gland dysfunction
por: Amano S, et al.
Publicado: (2017)

Ocular immunology and inflammation
Publicado: (1993)

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
por: Jariyakosol S, et al.
Publicado: (2021)

Comparative study of 0.1% hyaluronic acid versus 0.5% carboxymethylcellulose in patients with dry eye associated with moderate keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2018)

High Prevalence of Abnormal Ocular Surface Tests in a Healthy Pediatric Population
por: Rojas-Carabali W, et al.
Publicado: (2020)

Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination
por: Inoue K, et al.
Publicado: (2020)

Risk factors and clinical signs of severe Acanthamoeba keratitis
por: Shimmura-Tomita M, et al.
Publicado: (2018)

The UK Paediatric Ocular Trauma Study 2 (POTS2): demographics and mechanisms of injuries
por: Sii F, et al.
Publicado: (2018)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
por: Sambursky R
Publicado: (2016)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)